PD-L1-positive recurrent and metastatic cervical cancer responsive to first-line Sintilimab with chemotherapy plus Bevacizumab treatment: a case report

Hu Feng; FuJun Yang; Jingjing Mao; Shasha Bi; Shanshan Sun; Hongbo Yang; Haoxing Zhou; Shanshan Song

doi:10.22541/au.165003317.79010710/v1

loading page

PD-L1-positive recurrent and metastatic cervical cancer responsive to first-line Sintilimab with chemotherapy plus Bevacizumab treatment: a case report

Hu Feng,
FuJun Yang,
Jingjing Mao,
Shasha Bi,
Shanshan Sun,
Hongbo Yang,
Haoxing Zhou,
Shanshan Song

Abstract

Cervical cancer is the most common malignant tumor of the female reproductive system. Its incidence rate ranks first among that of female malignant tumors in China and has steadily increased in recent years [Juanjuan Jin et al., 2021].